Spruce biosciences to participate in the svb securities global biopharma conference

South san francisco, calif.--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that javier szwarcberg, m.d., m.p.h., chief executive officer, will present at the svb securities global biopharma conference on february 15, 2023, at 2:20 p.m. et. interested parties can access the live webcast here. an archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 30 days. about spruce biosciences spruce biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (cah). spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (pcos) with primary adrenal androgen excess. to learn more, visit www.sprucebiosciences.com and follow us on twitter @spruce_bio, linkedin, facebook and youtube.
SPRB Ratings Summary
SPRB Quant Ranking